SecSonar.com

BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

BioCryst Pharmaceuticals, Inc. (BCRX) is a Biotechnology company based in US with a market capitalization of $1.9B. Revenue grew 94.1% year-over-year and the company generated $327.4M in free cash flow. This page tracks BCRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 580 employees · IPO Mar 4, 1994

Valuation

Valuation & price

$9.02 · as of May 17, 2026 · -9.8% vs 52w high

7.5

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$10.00$8.15$6.30Jul 25Dec 25Jul 26Jul 7, 25$8.76Jul 9, 25$9.06Jul 11, 25$8.76Jul 15, 25$8.72Jul 17, 25$8.70Jul 21, 25$8.52Jul 23, 25$8.61Jul 25, 25$8.55Jul 29, 25$8.09Jul 31, 25$8.14Aug 4, 25$8.73Aug 6, 25$8.60Aug 11, 25$8.20Aug 13, 25$8.53Aug 15, 25$8.37Aug 19, 25$8.28Aug 21, 25$8.38Aug 25, 25$8.39Aug 27, 25$8.52Aug 29, 25$8.31Sep 3, 25$8.29Sep 5, 25$8.27Sep 9, 25$8.08Sep 11, 25$8.07Sep 16, 25$7.75Sep 18, 25$7.96Sep 22, 25$7.91Sep 24, 25$7.77Sep 26, 25$7.63Sep 30, 25$7.59Oct 2, 25$7.33Oct 6, 25$7.02Oct 8, 25$7.28Oct 10, 25$7.22Oct 14, 25$6.42Oct 16, 25$6.72Oct 21, 25$6.99Oct 23, 25$7.19Oct 27, 25$7.31Oct 29, 25$7.31Oct 31, 25$7.32Nov 4, 25$6.76Nov 6, 25$7.03Nov 10, 25$7.20Nov 12, 25$7.18Nov 14, 25$7.08Nov 18, 25$7.00Nov 20, 25$7.03Nov 25, 25$6.85Nov 28, 25$7.18Dec 2, 25$7.16Dec 4, 25$7.83Dec 8, 25$7.70Dec 10, 25$7.66Dec 12, 25$7.57Dec 16, 25$7.47Dec 18, 25$7.29Dec 22, 25$7.61Dec 24, 25$7.70Dec 29, 25$7.71Jan 2, 26$7.50Jan 6, 26$7.58Jan 8, 26$7.62Jan 12, 26$7.09Jan 14, 26$6.78Jan 16, 26$6.66Jan 21, 26$6.72Jan 23, 26$6.79Jan 27, 26$6.76Jan 29, 26$6.67Feb 2, 26$6.63Feb 4, 26$6.42Feb 9, 26$6.30Feb 11, 26$6.84Feb 13, 26$6.76Feb 18, 26$7.26Feb 20, 26$7.45Feb 24, 26$7.61Feb 26, 26$7.90Mar 2, 26$8.63Mar 4, 26$8.57Mar 6, 26$8.48Mar 10, 26$8.75Mar 12, 26$8.38Mar 17, 26$9.21Mar 19, 26$9.81Mar 23, 26$9.80Mar 25, 26$9.40Mar 27, 26$9.33Mar 31, 26$9.52Apr 2, 26$9.02Apr 7, 26$9.59Apr 9, 26$9.89Apr 13, 26$9.41Apr 15, 26$9.44Apr 17, 26$9.50Apr 22, 26$9.01Apr 24, 26$8.94Apr 28, 26$8.86Apr 30, 26$9.16May 4, 26$9.20May 6, 26$8.83May 8, 26$8.62May 12, 26$8.80May 14, 26$9.57May 18, 26$8.97May 20, 26$8.74May 22, 26$8.29May 28, 26$9.10Jun 1, 26$8.57Jun 3, 26$8.25Jun 5, 26$8.41Jun 9, 26$8.33Jun 11, 26$8.50Jun 15, 26$9.06Jun 17, 26$8.95Jun 22, 26$9.14Jun 24, 26$10.00Jun 26, 26$9.94Jul 2, 26$9.84
$6.2452-week range$10.00
Loading valuation history…

Fundamentals

Key fundamentals

$1.9B

Market cap

94.1%

Revenue growth (YoY)

97.8%

Gross margin

$327.4M

Free cash flow (USD)

$202.6M

Net debt

1.6%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$26.4MFY 2017$25.2MFY 2018$20.7MFY 2019$48.8MFY 2020$17.8MFY 2021$157.2MFY 2022$270.8MFY 2023$331.4MFY 2024$450.7MFY 2025$874.8M
$26.4M$874.8M

Free cash flow by year

2016 → 2025

FY 2016$-58.7MFY 2017$-41.5MFY 2018$-92.9MFY 2019$-89.9MFY 2020$-137.7MFY 2021$-144.5MFY 2022$-163.2MFY 2023$-97.3MFY 2024$-53.1MFY 2025$327.4M
-$58.7M$327.4M

Gross margin by year

2021 → 2025

FY 202195.4%FY 202297.6%FY 202398.6%FY 202497.2%FY 202597.8%
95.4%97.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventRestructuringJun 29, 2026Filing
  • 8-K eventStock Incentive Plan AmendedJun 12, 2026Filing
  • Insider sellInsider Sell $100KMcKee Amy E · Director · $100.3KMay 19, 2026Filing
  • Insider sellInsider Sell $596K · 10b5-1 PlanBarnes Alane P · Chief Legal Officer · $596.3KMay 15, 2026Filing
  • 8-K eventFinancial Results and Licensing AgreementMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventLicensing AgreementMay 4, 2026Filing

Questions

Frequently asked questions

What is BioCryst Pharmaceuticals, Inc.'s market cap?

BioCryst Pharmaceuticals, Inc. (BCRX) has a market capitalization of $1.9B.

What is BCRX's P/E ratio?

BCRX trades at a price-to-earnings ratio of 7.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

Are insiders buying BCRX stock?

SEC Form 4 filings show no open-market insider buys at BioCryst Pharmaceuticals, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

AAPG

Ascentage Pharma Group International

$1.9B

GLPG

Galapagos N.V.

$1.9B

ABCL

AbCellera Biologics Inc.

$1.9B

ZYME

Zymeworks Inc.

$1.9B

ADMA

ADMA Biologics, Inc.

$1.9B

SRPT

Sarepta Therapeutics, Inc.

$1.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.